Shifting from Immunohistochemistry to Screen for ALK Rearrangements: Real-World Experience in a Large Single-Center Cohort of Patients with Non-Small-Cell Lung Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Patients and Methods
2.1. ALK Immunohistochemistry
2.2. ALK Fluorescence In Situ Hybridization
2.3. Ultra-Fast Next-Generation Sequencing
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Solomon, B.J.; Mok, T.; Kim, D.W.; Wu, Y.L.; Nakagawa, K.; Mekhail, T.; Felip, E.; Cappuzzo, F.; Paolini, J.; Usari, T.; et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014, 371, 2167–2177. [Google Scholar] [CrossRef]
- Hendriks, L.E.; Kerr, K.M.; Menis, J.; Mok, T.S.; Nestle, U.; Passaro, A.; Peters, S.; Planchard, D.; Smit, E.F.; Solomon, B.J.; et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023, 34, 339–357. [Google Scholar] [CrossRef] [PubMed]
- Mosele, F.; Remon, J.; Mateo, J.; Westphalen, C.B.; Barlesi, F.; Lolkema, M.P.; Normanno, N.; Scarpa, A.; Robson, M.; Meric-Bernstam, F.; et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. Ann. Oncol. 2020, 31, 1491–1505. [Google Scholar] [CrossRef] [PubMed]
- Camidge, D.R.; Kono, S.A.; Flacco, A.; Tan, A.C.; Doebele, R.C.; Zhou, Q.; Crino, L.; Franklin, W.A.; Varella-Garcia, M. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res. 2010, 16, 5581–5590. [Google Scholar] [CrossRef]
- Wynes, M.W.; Sholl, L.M.; Dietel, M.; Schuuring, E.; Tsao, M.S.; Yatabe, Y.; Tubbs, R.R.; Hirsch, F.R. An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators. J. Thorac. Oncol. 2014, 9, 631–638. [Google Scholar] [CrossRef]
- Cabillic, F.; Hofman, P.; Ilie, M.; Peled, N.; Hochmair, M.; Dietel, M.; Von Laffert, M.; Gosney, J.R.; Lopez-Rios, F.; Erb, G.; et al. ALK IHC and FISH discordant results in patients with NSCLC and treatment response: For discussion of the question-to treat or not to treat? ESMO Open 2018, 3, e000419. [Google Scholar] [CrossRef] [PubMed]
- Cabillic, F.; Gros, A.; Dugay, F.; Begueret, H.; Mesturoux, L.; Chiforeanu, D.C.; Dufrenot, L.; Jauffret, V.; Dachary, D.; Corre, R.; et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J. Thorac. Oncol. 2014, 9, 295–306. [Google Scholar] [CrossRef] [PubMed]
- Clave, S.; Rodon, N.; Pijuan, L.; Diaz, O.; Lorenzo, M.; Rocha, P.; Taus, A.; Blanco, R.; Bosch-Barrera, J.; Reguart, N.; et al. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns. Clin. Lung Cancer 2019, 20, e421–e429. [Google Scholar] [CrossRef]
- Lin, H.M.; Wu, Y.; Yin, Y.; Niu, H.; Curran, E.A.; Lovly, C.M.; Humphries, M.J. Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States. Clin. Lung Cancer 2023, 24, e39–e49. [Google Scholar] [CrossRef]
- Ettinger, D.S.; Wood, D.E.; Aisner, D.L.; Akerley, W.; Bauman, J.R.; Bharat, A.; Bruno, D.S.; Chang, J.Y.; Chirieac, L.R.; D’Amico, T.A.; et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2022, 20, 497–530. [Google Scholar] [CrossRef]
- Penault-Llorca, F.; Kerr, K.M.; Garrido, P.; Thunnissen, E.; Dequeker, E.; Normanno, N.; Patton, S.J.; Fairley, J.; Kapp, J.; de Ridder, D.; et al. Expert opinion on NSCLC small specimen biomarker testing—Part 2: Analysis, reporting, and quality assessment. Virchows Arch. 2022, 481, 351–366. [Google Scholar] [CrossRef] [PubMed]
- Travis, W.D.; Brambilla, E.; Burke, A.P.; Marx, A.; Nicholson, A.G. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed.; IARC: Lyon, France, 2015. [Google Scholar]
- Shaw, A.T.; Kim, D.W.; Nakagawa, K.; Seto, T.; Crino, L.; Ahn, M.J.; De Pas, T.; Besse, B.; Solomon, B.J.; Blackhall, F.; et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368, 2385–2394. [Google Scholar] [CrossRef]
- Doebele, R.C.; Pilling, A.B.; Aisner, D.L.; Kutateladze, T.G.; Le, A.T.; Weickhardt, A.J.; Kondo, K.L.; Linderman, D.J.; Heasley, L.E.; Franklin, W.A.; et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 2012, 18, 1472–1482. [Google Scholar] [CrossRef] [PubMed]
- ISO 15189:2022; Medical Laboratories—Requirements for Quality and Competence. ISO: Geneva, Switzerland, 2022.
- Ilie, M.I.; Bence, C.; Hofman, V.; Long-Mira, E.; Butori, C.; Bouhlel, L.; Lalvee, S.; Mouroux, J.; Poudenx, M.; Otto, J.; et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: A potential major issue for anti-ALK therapeutic strategies. Ann. Oncol. 2015, 26, 238–244. [Google Scholar] [CrossRef]
- Ilie, M.; Hofman, V.; Bontoux, C.; Heeke, S.; Lespinet-Fabre, V.; Bordone, O.; Lassalle, S.; Lalvee, S.; Tanga, V.; Allegra, M.; et al. Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France). Cancers 2022, 14, 2258. [Google Scholar] [CrossRef] [PubMed]
- Zacharias, M.; Absenger, G.; Kashofer, K.; Wurm, R.; Lindenmann, J.; Terbuch, A.; Konjic, S.; Sauer, S.; Gollowitsch, F.; Gorkiewicz, G.; et al. Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing-a single-center experience. Transl. Lung Cancer Res. 2021, 10, 4221–4234. [Google Scholar] [CrossRef]
- Shreenivas, A.; Janku, F.; Gouda, M.A.; Chen, H.Z.; George, B.; Kato, S.; Kurzrock, R. ALK fusions in the pan-cancer setting: Another tumor-agnostic target? NPJ Precis. Oncol. 2023, 7, 101. [Google Scholar] [CrossRef]
- Soda, M.; Choi, Y.L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448, 561–566. [Google Scholar] [CrossRef]
- Hernandez, S.; Conde, E.; Alonso, M.; Illarramendi, A.; Bote de Cabo, H.; Zugazagoitia, J.; Paz-Ares, L.; Lopez-Rios, F. A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma. Transl. Lung Cancer Res. 2023, 12, 1549–1562. [Google Scholar] [CrossRef]
- Peters, S.; Camidge, D.R.; Shaw, A.T.; Gadgeel, S.; Ahn, J.S.; Kim, D.W.; Ou, S.I.; Perol, M.; Dziadziuszko, R.; Rosell, R.; et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017, 377, 829–838. [Google Scholar] [CrossRef]
- Gan, Q.; Roy-Chowdhuri, S. Small but powerful: The promising role of small specimens for biomarker testing. J. Am. Soc. Cytopathol. 2020, 9, 450–460. [Google Scholar] [CrossRef] [PubMed]
- Uruga, H.; Mino-Kenudson, M. ALK (D5F3) CDx: An immunohistochemistry assay to identify ALK-positive NSCLC patients. Pharmgenom. Pers. Med. 2018, 11, 147–155. [Google Scholar] [CrossRef] [PubMed]
- Letovanec, I.; Finn, S.; Zygoura, P.; Smyth, P.; Soltermann, A.; Bubendorf, L.; Speel, E.J.; Marchetti, A.; Nonaka, D.; Monkhorst, K.; et al. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. J. Thorac. Oncol. 2018, 13, 413–425. [Google Scholar] [CrossRef] [PubMed]
- Drilon, A.; Wang, L.; Arcila, M.E.; Balasubramanian, S.; Greenbowe, J.R.; Ross, J.S.; Stephens, P.; Lipson, D.; Miller, V.A.; Kris, M.G.; et al. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin. Cancer Res. 2015, 21, 3631–3639. [Google Scholar] [CrossRef] [PubMed]
- Hofman, V.; Heeke, S.; Bontoux, C.; Chalabreysse, L.; Barritault, M.; Bringuier, P.P.; Fenouil, T.; Benzerdjeb, N.; Begueret, H.; Merlio, J.P.; et al. Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC. JTO Clin. Res. Rep. 2023, 4, 100457. [Google Scholar] [CrossRef] [PubMed]
- Kazdal, D.; Hofman, V.; Christopoulos, P.; Ilie, M.; Stenzinger, A.; Hofman, P. Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications. Genes Chromosomes Cancer 2022, 61, 244–260. [Google Scholar] [CrossRef] [PubMed]
- Mitiushkina, N.V.; Romanko, A.A.; Preobrazhenskaya, E.V.; Tiurin, V.I.; Ermachenkova, T.I.; Martianov, A.S.; Mulkidjan, R.S.; Sokolova, T.N.; Kholmatov, M.M.; Bizin, I.V.; et al. Comprehensive evaluation of the test for 5′-/3′-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer. Cancer Med. 2022, 11, 3226–3237. [Google Scholar] [CrossRef]
- Rosenbaum, J.N.; Bloom, R.; Forys, J.T.; Hiken, J.; Armstrong, J.R.; Branson, J.; McNulty, S.; Velu, P.D.; Pepin, K.; Abel, H.; et al. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. Mod. Pathol. 2018, 31, 791–808. [Google Scholar] [CrossRef]
- Benayed, R.; Offin, M.; Mullaney, K.; Sukhadia, P.; Rios, K.; Desmeules, P.; Ptashkin, R.; Won, H.; Chang, J.; Halpenny, D.; et al. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clin. Cancer Res. 2019, 25, 4712–4722. [Google Scholar] [CrossRef]
- McLeer-Florin, A.; Duruisseaux, M.; Pinsolle, J.; Dubourd, S.; Mondet, J.; Phillips Houlbracq, M.; Magnat, N.; Faure, J.; Chatagnon, A.; de Fraipont, F.; et al. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. Lung Cancer 2018, 116, 15–24. [Google Scholar] [CrossRef]
- Dagogo-Jack, I.; Brannon, A.R.; Ferris, L.A.; Campbell, C.D.; Lin, J.J.; Schultz, K.R.; Ackil, J.; Stevens, S.; Dardaei, L.; Yoda, S.; et al. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. JCO Precis. Oncol. 2018, 2018, 1–14. [Google Scholar] [CrossRef] [PubMed]
- Singh, R.R. Target Enrichment Approaches for Next-Generation Sequencing Applications in Oncology. Diagnostics 2022, 12, 1539. [Google Scholar] [CrossRef] [PubMed]
- Williams, H.L.; Walsh, K.; Diamond, A.; Oniscu, A.; Deans, Z.C. Validation of the Oncomine() focus panel for next-generation sequencing of clinical tumour samples. Virchows Arch. 2018, 473, 489–503. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Zhang, B.; Zhang, Y.; Xu, F.; Zhang, Z.; Shao, L.; Yan, C.; Ulivi, P.; Denis, M.G.; Christopoulos, P.; et al. Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib. Transl. Lung Cancer Res. 2021, 10, 1525–1535. [Google Scholar] [CrossRef] [PubMed]
- Nadal, E.; Bautista, D.; Cabezon-Gutierrez, L.; Ortega, A.L.; Torres, H.; Carcedo, D.; Ruiz de Alda, L.; Garcia, J.F.; Vieitez, P.; Rojo, F. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario. BMC Cancer 2021, 21, 689. [Google Scholar] [CrossRef] [PubMed]
- Lindeman, N.I.; Cagle, P.T.; Aisner, D.L.; Arcila, M.E.; Beasley, M.B.; Bernicker, E.; Colasacco, C.; Dacic, S.; Hirsch, F.R.; Kerr, K.; et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch. Pathol. Lab. Med. 2018, 142, 321–346. [Google Scholar] [CrossRef] [PubMed]
- Buglioni, A.; Caffes, P.L.; Hessler, M.G.; Mansfield, A.S.; Lo, Y.C. Clinical Utility Validation of an Automated Ultrarapid Gene Fusion Assay for NSCLC. JTO Clin. Res. Rep. 2022, 3, 100434. [Google Scholar] [CrossRef] [PubMed]
- Depoilly, T.; Garinet, S.; van Kempen, L.C.; Schuuring, E.; Clave, S.; Bellosillo, B.; Ercolani, C.; Buglioni, S.; Siemanowski, J.; Merkelbach-Bruse, S.; et al. Multicenter Evaluation of the Idylla GeneFusion in Non-Small-Cell Lung Cancer. J. Mol. Diagn. 2022, 24, 1021–1030. [Google Scholar] [CrossRef]
- Conde, E.; Rojo, F.; Gomez, J.; Enguita, A.B.; Abdulkader, I.; Gonzalez, A.; Lozano, D.; Mancheno, N.; Salas, C.; Salido, M.; et al. Molecular diagnosis in non-small-cell lung cancer: Expert opinion on ALK and ROS1 testing. J. Clin. Pathol. 2022, 75, 145–153. [Google Scholar] [CrossRef]
- Canterbury, C.R.; Fernandes, H.; Crapanzano, J.P.; Murty, V.V.; Mansukhani, M.M.; Shu, C.A.; Szabolcs, M.; Saqi, A. ALK Gene Rearrangements in Lung Adenocarcinomas: Concordance of Immunohistochemistry, Fluorescence In Situ Hybridization, RNA In Situ Hybridization, and RNA Next-Generation Sequencing Testing. JTO Clin. Res. Rep. 2021, 2, 100223. [Google Scholar] [CrossRef]
Variable | Type | n (%) |
---|---|---|
All patients (n = 1246) | ||
Age [median (range)] | 68 (25–96) | |
Gender | ||
Male | 716 (57%) | |
Female | 530 (43%) | |
Smoking status | Smoker | 835 (67%) |
Non-smoker | 137 (11%) | |
Former smoker | 274 (22%) | |
Histological subtypes | Acinar adenocarcinoma | 648 (52%) |
Papillary adenocarcinoma | 174 (14%) | |
Micropapillary adenocarcinoma | 75 (6%) | |
Solid adenocarcinoma | 87 (7%) | |
Mucinous invasive adenocarcinoma | 50 (4%) | |
NSCLC, NOS | 125 (10%) | |
NSCLC, favoring adenocarcinoma | 87 (7%) | |
pTNM stage | ||
I | 50 (4%) | |
II | 87 (7%) | |
III | 274 (22%) | |
IV | 835 (67%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ilié, M.; Goffinet, S.; Rignol, G.; Lespinet-Fabre, V.; Lalvée, S.; Bordone, O.; Zahaf, K.; Bonnetaud, C.; Washetine, K.; Lassalle, S.; et al. Shifting from Immunohistochemistry to Screen for ALK Rearrangements: Real-World Experience in a Large Single-Center Cohort of Patients with Non-Small-Cell Lung Cancer. Cancers 2024, 16, 2219. https://doi.org/10.3390/cancers16122219
Ilié M, Goffinet S, Rignol G, Lespinet-Fabre V, Lalvée S, Bordone O, Zahaf K, Bonnetaud C, Washetine K, Lassalle S, et al. Shifting from Immunohistochemistry to Screen for ALK Rearrangements: Real-World Experience in a Large Single-Center Cohort of Patients with Non-Small-Cell Lung Cancer. Cancers. 2024; 16(12):2219. https://doi.org/10.3390/cancers16122219
Chicago/Turabian StyleIlié, Marius, Samantha Goffinet, Guylène Rignol, Virginie Lespinet-Fabre, Salomé Lalvée, Olivier Bordone, Katia Zahaf, Christelle Bonnetaud, Kevin Washetine, Sandra Lassalle, and et al. 2024. "Shifting from Immunohistochemistry to Screen for ALK Rearrangements: Real-World Experience in a Large Single-Center Cohort of Patients with Non-Small-Cell Lung Cancer" Cancers 16, no. 12: 2219. https://doi.org/10.3390/cancers16122219
APA StyleIlié, M., Goffinet, S., Rignol, G., Lespinet-Fabre, V., Lalvée, S., Bordone, O., Zahaf, K., Bonnetaud, C., Washetine, K., Lassalle, S., Long-Mira, E., Heeke, S., Hofman, V., & Hofman, P. (2024). Shifting from Immunohistochemistry to Screen for ALK Rearrangements: Real-World Experience in a Large Single-Center Cohort of Patients with Non-Small-Cell Lung Cancer. Cancers, 16(12), 2219. https://doi.org/10.3390/cancers16122219